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Background: In this study, we further investigated the association of two biomarkers, CCL18 and A1AT, with
bladder cancer (BCa) and evaluated the influence of potentially confounding factors in an experimental model.
Methods: In a cohort of 308 subjects (102 with BCa), urinary concentrations of CCL18 and A1AT were assessed by
enzyme-linked immunosorbent assay (ELISA). In an experimental model, benign or cancerous cells, in addition to
blood, were added to urines from healthy controls and analyzed by ELISA. Lastly, immunohistochemical staining for
CCL18 and A1AT in human bladder tumors was performed.
Results: Median urinary protein concentrations of CCL18 (52.84 pg/ml vs. 11.13 pg/ml, p < 0.0001) and A1AT
(606.4 ng/ml vs. 120.0 ng/ml, p < 0.0001) were significantly elevated in BCa subjects compared to controls.
Furthermore, the addition of whole blood to pooled normal urine resulted in a significant increase in both CCL18
and A1AT. IHC staining of bladder tumors revealed CCL18 immunoreactivity in inflammatory cells only, and there
was no significant increase in these immunoreactive cells within benign and cancerous tissue and no association
with BCa grade nor stage was noted. A1AT immunoreactivity was observed in the cytoplasm of epithelia cells and
intensity of immunostaining increased with tumor grade, but not tumor stage.
Conclusions: Further development of A1AT as a diagnostic biomarker for BCa is warranted.
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Non-invasive urine tests for the early detection or post-
surgical surveillance of bladder cancer (BCa) are highly
desirable for both the patient and the healthcare system.
Currently, voided urinary cytology (VUC) is the most
widely used non-invasive urine test, with reported speci-
ficities ranging from 85-100% and sensitivities ranging
from 13-75% [1,2]. Two single-protein biomarker urine-
based assays, bladder tumor antigen (BTA) test and
nuclear matrix protein-22 (NMP-22) test, have been
developed and FDA approved for use in this context.
However, these assays have significant limitations. The
BTA tests (BTA stat™ and BTA TRAK™ (Polymedco Inc.
Cortlandt Manor, NY, USA) have diagnostic sensitivities
ranging from 29-83% and specificities ranging from 56-86%* Correspondence: deacdoc@aol.com
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stated.[3,4]. In addition, we and others have demonstrated in an
experimental model that hematuria adversely affects the
accuracy of the BTA assay [5,6]. The NMP-22 tests
(NMP22® Bladder Cancer ELISA Test Kit and the NMP22®
BladderChek® point-of-care test, Alere Scarborough, Inc.
Waltham, MA) have diagnostic sensitivities ranging from
47-100% and specificities ranging from 55-98% [7,8].
Atsu et al. and others have recently demonstrated in an ex-
perimental model that NMP-22 assays measure the cellular-
ity or amount of cell turnover that may be introduced into
the urine by a variety of conditions, including hematuria,
infection and instrumentation [9,10]. Thus, the search for
more accurate urine-based biomarkers continues.
Through genomic and proteomic profiling of urine
components, we have previously identified a panel of
biomarkers that can outperform current urine-based
biomarkers for the non-invasive detection of BCa
[11-14]. In a case-controlled validation study, the urinary
concentrations of our panel of 14 biomarkers (IL-8,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ANG, CA9, A1AT, SPP1, PTX3, and APOE) were mea-
sured by enzyme-linked immunosorbent assay (ELISA)
in voided urines from 127 patients (64 tumor bearing
subjects) [15-18]. Of these 14 biomarkers, two bio-
markers (CCL18 and A1AT) had high correlation coeffi-
cients (Spearman correlation coefficient >0.76) with
urinary blood content and therefore, rather than measur-
ing a valid tumor antigen the biomarker may be merely a
surrogate for hematuria. Subsequently, these two bio-
markers have been excluded from ongoing multiplex stud-
ies [19] until we can clarify the source of these protein
biomarkers. Herein, we report the urinary concentrations
of CCL18 and A1AT in an independent larger case–con-
trol study, and illustrate in an experimental model the
influence of cellular proteins and whole blood on the per-
formance of these potential urine-based biomarkers.Methods
Ethics statement
Under Institutional Review Board approval by the com-
mittees at MD Anderson Cancer Center Orlando and
Hospital Clinic of Barcelona, written informed consent
was obtained prior to collection and storage of biological
specimens (voided urine samples and blood) in genito-
urinary biorepositories. Furthermore under Institutional
Review Board approval by the committee at MD Anderson
Cancer Center Orlando with a waiver of written informed
consent, archived bladder tissues from the Department of
Pathology at Orlando Health was identified for immuno-
histochemical analysis. The above review boards moni-
tored study recruitment and study compliance.Patients and data collection
For the urinary ELISA validation study, 308 non-
consecutive subjects (102 with BCa) from MD Anderson
Cancer Center Orlando and Hospital Clínic of Barcelona
were available for analysis. The control cohort consisted of
206 individuals (47 with voiding symptoms, 44 with uro-
lithiasis, 9 with gross hematuria, 14 with urinary tract in-
fection and 92 without any diagnosed condition). Patients
with a history of renal dysfunction were excluded. The
cohort of 308 subjects served as our phase II (validation
study) according to the International Consensus Panel on
Bladder Tumor Markers and findings were reported
according to the STARD criteria [20]. For the experimen-
tal model, three healthy volunteers (2 males, 1 female,
mean age 36 years) provided urine and blood samples. For
the immunohistochemical study, formalin-fixed paraffin
embedded blocks containing 165 bladder tumor tissue
specimens and 8 benign tissue specimens were retrieved
from the Orlando Health Department of Pathology.Specimen processing
Fifty milliliters of voided urine from each subject was
assigned a unique identifying number before delivery to
the laboratory for processing. Each urine sample was
centrifuged at 1000 × g 4°C for 10 min. The supernatant
was decanted and aliquoted, and the urinary pellet was
snap frozen. Both the supernatant and pellet were stored
at -80°C prior to analysis. Urine supernatant protein con-
centration was determined using Pierce 660-nm Protein
Assay Kit (Thermo Fisher Scientific Inc., Waltham, MA,
USA). Patients with significant proteinuria were excluded.
Enzyme-linked immunosorbent assays for urinary CCL18
and A1AT
The levels of human CCL18 (Cat # ab100620, Abcam,
Cambridge, MA) and human A1AT (Cat# ab108799,
Abcam) in urine samples were monitored using ELISA.
The assays were conducted according to the manufac-
turer’s instructions. Laboratory personnel were blinded to
final diagnosis. Calibration curves were prepared using
purified standards for each protein assessed. Curve fitting
was accomplished by either linear or four-parameter logis-
tic regression following manufacturer’s instructions. Urin-
ary creatinine levels were monitored with a commercial
ELISA assay (Cat# KGE005 R&D Systems Inc., Minneap-
olis, MN, USA) as previously described [21].
Cell lines and culture
Human bladder cancer cell lines T24 (ATCC, Manassas,
VA) and UM-UC-14 (a generous gift from Dr. H. Bart
Grossman, The University of Texas M.D. Anderson Can-
cer Center, Houston, TX) [22] were available for analysis.
The benign human bladder cell line, UROtsa, was a gen-
erous gift from Dr. Donald Sens at the University of
North Dakota School Of Medicine (Grand Forks, ND)
[23]. T24 and UM-UC-14 cell lines were maintained in
RPMI 1640 media. UROtsa cells were maintained in
McCoy’s 5A medium (Life Technologies, Inc., Gaithers-
burg, MD). All media were supplemented with 10% fetal
bovine serum, 100 units/ml of penicillin and 100 μg/ml
of streptomycin. All cells were incubated at 37°C in a
humidified atmosphere of 5% CO2.
Experimental model
The experimental model was essentially as previously
published [6,10]. Figure 1 illustrates the experimental
model components and dilutions. Briefly, 10 milliliters
of whole blood in heparinized tube and 200 ml of freshly
voided urine samples in sterile containers were obtained
from three healthy controls. The urine samples from the
three healthy subjects were pooled, mixed and distrib-
uted into 10 ml aliquots in 15 ml centrifuge tubes. The
human bladder cell lines were washed, trypsinized and
counted. For UROtsa, 1×104 cells (low concentration),
Figure 1 Schematic of the experimental model. Low
concentration (1×104), medium concentration (1×105) and high
concentrations (1×106) of intact UROtsa benign human bladder cells,
or a mixture of human bladder cancer lines, T24 and UM-UC-14
were added to 10 ml of pooled urine from three healthy controls.
Low protein concentration of cellular lysate (4 μg), medium
concentration (40 μg) and high concentrations (400 μg) of UROtsa
benign human bladder cells, or from a mixture of human bladder
cancer lines, T24 and UM-UC-14 were added to 10 ml of pooled
urine from three healthy controls. Whole blood (1, 5, 20 and 50 μl)
was also added to 10 ml of pooled urine from healthy controls.
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(high concentration) cells were each added to 10 ml
pooled urine samples in triplicate. Equal numbers of
T24 and UM-UC-14 were pooled, and 1×104 pooled
cells (low concentration), 1×105 pooled cells (medium
concentration) and 1×106 pooled cells (high concentra-
tion) cells were added to 10 ml of pooled urine samples
in triplicate. For cell lysate analyses, 1×106 cells from
each cell line were lysed with RIPA buffer (Pierce, Rock-
ford, IL) and total protein concentration measured. The
total protein extracted from 1×106 cells of UROtsa, T24
and UM-UC-14 were 431 μg, 471 μg, 280 μg and
420 μg, respectively, with a mean total protein extract of
400 μg. In the spiking experiments, 4 μg, 40 μg and
400 μg of cellular proteins from either UROtsa or the
pooled BCa cell lines were used, corresponding to
~1×104 cells (low concentration), ~1×105 cells (medium
concentration) and ~1×106 cells (high concentration).UROtsa lysates and pooled cancer cell lysates were
added to pooled urine samples in triplicate. To monitor
the influence of hematuria, pooled whole blood from
three healthy subjects was added in triplicate to 10 ml of
pooled urine samples in the following amounts; 1 μl, 1/
10000 final dilution; 5 μl, 1/2000 final dilution; 20 μl, 1/
500 final dilution; 50 μl, 1/200 final dilution and zero
control. The number of red blood cells (RBC) in each
urine sample was determined by microscopic examin-
ation before and after adding whole blood. Standard
urinalysis was performed with MULTISTIX PRO Re-
agent Strips (Bayer HealthCare, Elkhart, IN).
Immunohistochemistry
A total of 173 paraffin blocks were verified histologically by
H&E staining. For immunochemical staining, blocks were
cut in 5 μm sections and placed on a Superfrost Plus
Miscroslide. Sections were deparaffinized, followed by anti-
gen retrieval using citric acid buffer (pH 6.0, 95°C for 20
min). The slides were treated with 1% hydrogen peroxide in
methanol to block endogenous peroxidase activity. After 20
min blocking in 1% bovine serum albumin (BSA), the slides
were incubated overnight at 4°C with anti-human CCL18
antibody (MAB394; mouse monoclonal, dilution 1/500 in
1% BSA) from R&D Systems Inc., or anti-human A1AT
antibody (NBP1-90309; rabbit polyclonal, dilution 1/2500
in 1% BSA) from Novus Biologicals Inc. (Littleton, CO).
Next, the slides were incubated with 2 μg/mL of
biotinylated anti-mouse or anti-rabbit IgG secondary anti-
body (Vector Laboratories, Burlingame, CA) for 30 min at
room temperature. Subsequently, the sections were stained
using Standard Ultra-Sensitive ABC Peroxidase Staining kit
(Pierce/Thermo Fisher Scientific, San Jose, CA) and 3, 3'-
diaminobenzidine (DAB; Vector Laboratories), counter-
stained by hematoxylin, dehydrated, and mounted with a
cover slide. Human liver, known to stain strongly for
CCL18 and A1AT, was used as a positive control, and nega-
tive controls were performed by omitting the primary anti-
bodies. Using light microscopy, two investigators (MM and
AL) interpreted immunostaining results blinded to speci-
men and patient data. A third investigator (CJR) reviewed
discrepancies and rendered a final score. The location of
immunoreactivity (e.g., nuclear, cytoplasm, cell membrane,
and stroma) was noted. CCL18 immunostaining was posi-
tive only in inflammatory cells in the stroma. Three ran-
domly chosen high power fields (1 HPF = 0.237 mm2) were
analyzed for CCL18-positive cells in the stromal area and
averaged in each case. A1AT immunostaining was positive
only in the cytoplasm of epithelial cells. Immunostaining
intensity was reported as weak, moderate or strong.
Data analysis
The Wilcoxon rank sum test was used on ELISA data to
determine the association between urinary CCL18,
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ing characteristic (ROC) curves were plotted and the
ability of the biomarker to predict the presence of
BCa was estimated by calculating the area under the
ROC curves (AUROC). The sensitivity and specificity
of the biomarker at the optimal cutoff value was
defined by calculating the Youden index [24]. Com-
parison of immunohistochemical distribution data was
performed using Chi square test. Spearman rank
correlation coefficients were used to examine the cor-
relation between urinary CCL18 and A1AT concentra-
tions and urinary hemoglobin concentration. The
association between CCL18 and A1AT levels and BCa
was tested using the Mann Whitney test. Statistical
significance in this study was set at p < 0.05 and
all reported p values were 2-sided. All analyses
were performed using PRISM software version 5.00
(San Diego, CA).Table 1 Demographic and clinicopathologic characteristics of
subjects comprising IHC study cohort
ELISA Coh
BCa (%) n = 102 Co
Median Age (range, y) 69 (20 – 93)
Male : Female ratio 84 : 18
Race
White 91 (90%)
African American 5 (5.9%)
Other 6 (6.1%)
Positive FISH 40 / 74 (54%)
Suspicious/positive cytology 37 / 94 (39%)
Median follow-up (months) 14
Clinical stage
Tis 6 (6%)
Ta 41 (40%)
T1 14 (14%)
≥T2 41 (40%)
Tumor grade
Low 38 (37%)
High 64 (63%)
Median tumor size (cm) 3.0
Median urinary CCL18 pg/ml (range) 52.84
(2–6949)
Median urinary A1AT ng/ml (range) 606.4
(26–8830)
Median urinary protein μg/ml (range) 24.2
(24–789)Results
CCL18 and A1AT in voided urine samples
Table 1 depicts demographics and clinical characteristics
of the study cohorts. Ninety percent of the BCa subjects
sampled were Caucasian (median age 69 years) with 60%
noted to have non-muscle invasive bladder cancer
(NMIBC) and 37% with low-grade disease. In the cancer
cohort, urinary cytology achieved a diagnostic sensitivity
of 39%. Median urinary protein concentrations of
CCL18 (52.84 pg/ml vs. 11.13 pg/ml, p < 0.0001) and
A1AT (606.4 ng/ml vs. 120 ng/ml, p < 0.0001) were sig-
nificantly elevated in BCa subjects compared to controls.
Furthermore, median urinary CCL18 was significantly
elevated in muscle invasive bladder cancer (MIBC)
compared to NMIBC (90.65 pg/ml vs. 44.72 pg/ml,
p = 0.044), and approached significance (Figure 2a) in
high-grade compared to low-grade disease (79.57 pg/ml
vs. 38.10 pg/ml, p = 0.073). Similarly, median urinary308 subjects comprising ELISA study cohort and 173
ort IHC Cohort
ntrols (%) n = 206 BCa (%) n = 165 Controls (%) n = 8
56 (18 – 89) 67 (47 – 91) 59 (42 – 83)
152 : 54 132 : 33 7 : 1
135 (66%) 137 (83%) 7 (88%)
20 (10%) 8 (5%) 0 (0%)
51 (24%) 20 (12%) 1 (12%)
2/22(9%) N/A N/A
2/22(9%) N/A N/A
4 11 3
15 (9%)
15 (9%)
15 (9%)
120 (73%)
36 (22%)
129 (78%)
3.5
11.13
(0–662)
120.0
(1–1997)
38.9
(24–561)
Figure 2 Urinary biomarker levels. a) Comparison of urine concentrations of CCL-18 between the cancer and non-cancer groups (left panel),
low-grade and high-grade (middle panel) and non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). b)
Comparison of urine concentrations of A1AT between the same groups. Median levels are depicted by horizontal lines within boxes, standard
deviations are depicted by bars. Significance (p < 0.05) was assessed by the Wilcoxon rank sum test.
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NMIBC (978.1 ng/ml vs. 414.5 ng/ml, p = 0.0042) and
approached significance (Figure 2b) in high-grade
compared to low-grade (917.8 ng/ml vs. 414.5 ng/ml,
p = 0.073). The ability of the tested biomarkers to pre-
dict the presence of BCa was analyzed using nonpara-
metric ROC analyses, according to National Cancer
Institute guidelines [25]. Based on the AUROC, we de-
termined Youden index cutoff values to maximize the
sum of sensitivity and specificity. Urinary CCL18 had an
area under the curve of 0.768 (95% CI: 0.713-0.824)
(Figure 3), achieved a sensitivity of 70.4%, specificity of
67.7%, positive predictive value of 53.1% and a negative
predictive value of 81.5%. Urinary A1AT had an area
under the curve of 0.775 (95% CI: 0.721-0.829) (Figure 3),
achieved a sensitivity of 70.6%, specificity of 71.8%, posi-
tive predictive value of 55.4% and negative predictive
value of 83.2%.
Experimental model
Urine and blood samples were obtained from three
healthy volunteer controls for analysis in the experimen-
tal model. There was no evidence of gross hematuria,
urinary tract infection or any biochemical abnormalities
in any volunteer urine samples. Both urinary dipstick
and urinary microscopy were negative for hematuria,however, urinary hemoglobin measured by ELISA assay
revealed trace amounts in all samples (3.63 ± 0.59 ng/
ml). In these healthy controls, the mean urinary CCL18
level was 5.96 ± 7.73 pg/ml, and the mean urinary A1AT
level was 1170 ± 71.94 ng/ml (Table 2).
Urine samples were pooled, and whole cells or cell
lysates of the cancer cell line pool and UROtsa cells were
added to the urine sample (as depicted in Figure 1) and
re-analyzed for CCL18 and A1AT using ELISA. The
addition of a high concentration (400 μg) of protein lys-
ate from UROtsa cells, or medium to high concentration
(40 μg to 400 μg) of protein lysate from pooled cancer-
ous cells resulted in a significant increase in test sample
CCL18 (Additional file 1). Furthermore, the addition of
whole blood (50 μL) resulted in a significant increase in
CCL18 (p < 0.05) (Figure 4). As for A1AT, the addition
of high concentration of whole blood (50 μL) resulted
in a significant increase in test sample A1AT levels
(p < 0.05) (Figure 4).
With the addition of only 1 μl of whole blood to
10 mL of test urines (1/10,000 dilution), the mean urinary
hemoglobin level was 174.28 ± 15.69 ng/ml, and micros-
copy revealed a median 1 RBC/hpf. This level would be
termed ‘Negative’ or ‘Trace’ in clinical tests such as the
Multistix Pro dipstick test (negative blood is <100ng/ml).
At this level, CCL18 and A1AT concentrations were
Figure 3 Diagnostic performance of urinary CCL18 and A1AT. Receiver operator characteristic (ROC) curves were calculated from the analysis of
urine samples obtained from a cohort of 308 subjects (102 with confirmed bladder cancer) for CCL18 and A1AT. AUROC, area under the ROC curve.
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respectively. With the addition of 50 μl of whole blood to
10 mL of urine, all urines had visibly gross hematuria, the
mean urinary hemoglobin level was 7,898.05 ± 184.67 ng/
ml and median of 17 RBC/hpf was noted. At this level,
CCL18 concentration was raised to 31.90 ± 43.19 ng/ml
(~4.5 fold increase), but the A1AT concentration was
similar to controls at 1,273.16 ± 5.53 ng/ml (Table 2). As
the concentration of whole blood added to the urine sam-
ples increased, the mean urinary hemoglobin level, the ex-
tent of hematuria assessed by microscopy, and the mean
urinary concentrations of CCL18 and A1AT increased ac-
cordingly (Table 2). There were high correlation coeffi-
cients between hemoglobin and CCL18 (Spearman
correlation coefficient = 0.90) and hemoglobin and A1AT
(Spearman correlation coefficient = 1.00).Immunohistochemical analysis of bladder tumors
The study cohort consisted of 8 subjects without cancer
and 165 non-consecutive subjects with BCa (37 subjects
with low-grade BCa and 128 subjects with high-grade
BCa, 45 subjects with NMIBC and 120 MIBC). Immu-
nohistochemical staining patterns for CCL18 and A1AT
were assessed in both malignant and normal bladder tis-
sue. No epithelial staining was evident for CCL18, how-
ever, inflammatory cells in the stromal were positive.Table 2 Results of CCL18 and A1AT in experimental hematuri
Dilution (volume
of whole blood)
Red blood
cells ( /hpf * )
Con
Hemoglobin (ng/ml)
0 0 ± 0 3.63 ± 0.59
1/10,000 (1 μl) 0.6 ± 1.0 174.28 ± 15.69
1/2,000 (5 μl) 2.4 ± 1.2 2289.34 ± 479.07
1/500 (20 μl) 10.0 ± 4.4 3633.39 ± 2006.87
1/200 (50 μl) 17.3 ± 3.0 7898.05 ± 184.67
*hpf high power field.The number of CCL18-positive inflammatory cells per
high power field was not increased in bladder tumors
compared to controls (1.0 ± 1.2 vs. 4.5 ± 6.9, p = 0.57).
In addition, an increase in CCL18-positive inflammatory
cells was not associated with higher grade or higher
stage disease (Figure 5a). Immunostaining for A1AT
revealed a predominantly epithelial and cytoplasmic
localization. Intensity of staining ranged from weak
and focal to strong and diffuse. No difference in
staining intensity was seen between benign and can-
cer (p = 0.99). Staining intensity increased with an in-
crease in tumor grade (p = 0.05), however, staining
pattern was not significantly associated with tumor
stage (p = 0.79) (Figure 5b).Discussion and conclusions
We have previously identified CCL18 and A1AT as
potential biomarkers for the detection of BCa in voided
urine samples [15,18]. CCL18 is a member of the serum-
based cytokine family of secreted proteins involved in
immunoregulatory and inflammatory processes. CCL18
is thought to promote the invasiveness of cancer cells
by triggering integrin clustering and enhancing their
adherence to the extracellular matrix, and a receptor
(PITPNM3) for this cytokine has been recently identified
[26]. CCL18 has been identified in gynecological tumorsa model
centration (mean ± SD) Urinary protein
(dipstick test)CCL18 (pg/ml) A1AT (ng/ml)
5.96 ± 7.73 1170.70 ± 71.94 negative
7.06 ± 7.78 1227.31 ± 1.22 negative
6.80 ± 9.61 1252.49 ± 2.92 30 mg/dL
16.62 ± 22.17 1258.43 ± 13.48 100 mg/dL
31.90 ± 43.19 1273.16 ± 5.53 300 mg/dL
Figure 4 Analysis of CCL18 and A1AT biomarker performance
in an experimental model. Using the experimental model
depicted in Figure 1, urinary levels of CCL18 and A1AT were
analyzed by ELISA. The addition of whole blood resulted in an
increase in CCL18 as well as an increase in A1AT. Error bars indicate
standard deviations. *, significance (p < 0.05) compared to pooled
urines from healthy subjects. ^, significance (p < 0.05) compared to
corresponding lower concentration.
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SERPINA1, is a member of a family of serine proteases
inhibitors. Specifically A1AT irreversibly inhibits trypsin,
chymotrypsin and plasminogen activator. Serpins are
known to have diverse but critical roles in the cell, in-
cluding regulation of homeostasis, cellular survival and
blood clotting [29]. Within the oncology literature, re-
ports describe genetic aberrations in cancers, elevated
levels in the sera of cancer patients, and survival disad-
vantage in tumors expressing A1AT [30,31].
In our early studies, we noted that these biomarkers
had a relatively high correlation (Spearman correlation
coefficient > 0.76) with urinary hemoglobin. Given the
confounding effects of hematuria that we and others
have described for the urine-based BCa detection assays
BTA and NMP-22 [6,10], we set out to more methodic-
ally analyze the association of CCL18 and A1AT with
BCa by analyzing cohorts of urine and tissue samples. In
this study, ELISA analysis of urine samples from a co-
hort of 308 subjects confirmed our previous findings
[19] that both CCL18 and A1AT are significantly ele-
vated in the urines of subjects with BCa.
To investigate the potential influence of hematuria
and other factors on the performance of these bio-
markers we employed an experimental model. Although
the model does not mimic the actual physiological situ-
ation exactly, it does enable the identification of poten-
tial sources of specific analytes and to what extent
incursion of blood components into the urine may
influence the data. We previously used a similar model
approach to demonstrate that BTA urine tests primarily
detect a serum-based protein [6], and that NMP-22urine tests monitor cellular turnover, rather a specific
bladder tumor antigen [10].
Analyses from the model and the ELISA assays re-
vealed different characteristics for CCL18 and A1AT
with respect to them being potentially reliable BCa diag-
nostic biomarkers. For CCL18, the first observation is
that three healthy control samples had very low urinary
CCL18 levels (5.96 pg/ml). The median level of CCL18
in the non-cancer samples from the 308 subject cohort
was also very low (23.4 pg/ml). A low baseline level is an
advantage that can enable a clear distinction between
healthy and disease state for a given assay. Conversely, if
the differential between urine and blood is large, then a
small amount of hematuria may have a significant im-
pact. In the spiking experiment, we observed that 50 μl
of blood in 10 ml of urine, a level that would be termed
‘gross hematuria’ in clinical tests, raised the CCL18 level
in healthy controls to 31.9 pg/ml, an increase of ~5.3
fold. In the 308 subject cohort, the median level of
CCL18 was 10-fold higher in BCa subjects (230.5 pg/ml
vs. 23.4 pg/ml). The addition of benign and tumor cell
lysates to the urine sample is designed to indicate
whether the release of ubiquitous cellular factors may be
the source of the biomarker. Increased cellular turnover
is to be expected in a malignant condition, and so such
factors, for example NMP22, may increase even though
they are not actually cancer-specific biomarkers. Due to
the low levels of CCL18 in the healthy urine samples,
the addition of cell lysates from benign and tumor cells
did significantly impact the CCL18 levels. Finally, immu-
nohistochemical analysis of bladder tumor tissues re-
vealed that CCL18 was present only in the inflammatory
cells located in the stroma. No difference in the number
of the immunoreactive cells was observed in benign ver-
sus cancerous tissue, or among the various grades or
stages of bladder cancer. Together, these findings sug-
gest that CCL18 monitoring is unlikely to be a reliable
biomarker for the non-invasive detection of BCa.
The analysis of the A1AT biomarker revealed opposite
characteristics for the most part. ELISA data and the ex-
perimental model confirmed that A1AT is present at
high levels in healthy and non-cancer subject urine sam-
ples. The median level in the 308 subject cohort was 120
ng/ml in non-cancer cases, rising 5.5-fold to 606.4
ng/ml in subjects with confirmed BCa. The median level
in the three healthy volunteer samples was intermediate
(1,170 ng/ml). Lower levels in the non-cancer subjects
from the ELISA data is most likely due to degradation
with freezing and storage in these samples compared to
the fresh urines obtained from the volunteers. The high
baseline level of A1AT in healthy urine samples may not
be ideal for diagnostic evaluation, but the impact of
hematuria on A1AT assays would be expected to be less
pronounced. Accordingly, gross hematuria in the
Figure 5 Assessment of CCL18 and A1AT in bladder tissue. a) Representative immunostaining of benign bladder for CCL18 (top-left), low-
grade non-muscle invasive bladder cancer for CCL18 (top-middle), and high-grade muscle invasive bladder cancer for CCL18 (top-right). Red
arrows indicate CCL18-positive cells in the stroma. CCL18 staining was present only in inflammatory cells associated with the stroma. Lower
panels are boxplots of CCL18 immunohistochemical staining intensity of benign bladder vs. bladder cancer, low-grade vs. high-grade, non-muscle
invasive bladder cancer (NMIBC) vs. muscle invasive bladder cancer (MIBC). Error bars indicate standard deviations. Wilcoxon rank sum test was
used to assess significance. b) Representative immunostaining of benign bladder for A1AT (top-left), low-grade non-muscle invasive BCa for A1AT
(top-middle), and high-grade muscle invasive BCa for A1AT (top-right). A1AT staining was present in the cytoplasm and stroma. A1AT staining
varied from weak and focal to strong and diffuse. Lower panel shows column bar graphs of A1AT immunohistochemical staining intensity of
benign bladder vs. bladder cancer, low-grade vs. high-grade, NMIBC vs. MIBC.
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http://www.biomedcentral.com/1471-2490/13/42experimental model (50 μl of blood into 10 ml of urine)
raised A1AT to 1,273 ng/ml, an increase of only 9%.
Compare this to the >400% rise in CCL18 in the same
experimental model conditions. The addition of benign
or cancer cell lysates in the experimental model had no
impact on the A1AT levels. Previous preliminary re-
search has linked the presence of urinary A1AT as abiomarker for renal dysfunction [32]. However we took
precautions in our study to minimize renal dysfunction
as a confounder by excluding subjects with a history of
renal dysfunction as well as exclude subjects with grossly
elevated urinary protein levels. Recently, researchers
have reported that impaired renal function (i.e., reduced
glomerular filtration rate) may adversely affect urinary
Miyake et al. BMC Urology 2013, 13:42 Page 9 of 10
http://www.biomedcentral.com/1471-2490/13/42biomarkers performance [33,34]. This is an excellent
point and should be taken into consideration in future
studies. However, we must stress that we confirmed
these A1AT ELISA results by performing immunohisto-
chemistry and thus demonstrated that A1AT is present
within urothelial cells. We reported A1AT reactivity was
epithelial in normal bladder tissue, and strongly positive
in all tumor cells, specifically high-grade cells. Although
A1AT IHC may not be particularly useful in differential
histological evaluations, it does suggest that the source
of the increased A1AT observed in BCa samples is most
likely bladder tumor cells. The release into the urine
may be via secretion or the turnover of tumor cells at
the urine interface. Thus, even though normal urinary
levels of A1AT are relatively high, measurement of this
biomarker in the context of cancer detection may be
worthwhile. The good separation between non-cancer
and BCa urinary levels and the limited influence by
secondary sources suggest that valid diagnostic cut-
off thresholds may be possible for urinary A1AT
monitoring.
When novel urinary biomarkers are proposed, the
investigation of reliability in the face of potentially
confounding effects is warranted, especially those intro-
duced into the urine through bleeding, a common pre-
senting factor in bladder tumor-bearing patients.
Further studies into the utility of A1AT as a biomarker
for the non-invasive detection of BCa are currently
underway.
Additional file
Additional file 1: Analysis of CCL18 and A1AT biomarker
performance in an experimental model. Using the experimental
model depicted in Figure 1, urinary levels of CCL18 and A1AT were
analyzed by ELISA. The addition of high concentration of benign cell lysate
or medium to high concentration of cancer cell lysate resulted in an
increase in CCL18. The addition of cells or cell lysate did not alter A1AT
levels. Error bars indicate standard deviations. *, significance (p < 0.05)
compared to pooled urines from healthy subjects. ^, significance (p < 0.05)
compared to corresponding lower concentration.
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